Terms: = Thyroid cancer AND HER1, YOR227W
15 results:
1. Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z; Grandis JR; Johnson DE
Expert Opin Emerg Drugs; 2022 Sep; 27(3):333-344. PubMed ID: 36131561
[TBL] [Abstract] [Full Text] [Related]
2. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
3. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract] [Full Text] [Related]
4. Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells.
Ota I; Higashiyama S; Masui T; Yane K; Hosoi H; Matsuura N
Oncol Rep; 2013 Oct; 30(4):1593-600. PubMed ID: 23917679
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract] [Full Text] [Related]
6. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract] [Full Text] [Related]
7. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
Wiseman SM; Griffith OL; Melck A; Masoudi H; Gown A; Nabi IR; Jones SJ
Am J Surg; 2008 May; 195(5):667-73; discussion 673. PubMed ID: 18424286
[TBL] [Abstract] [Full Text] [Related]
9. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races.
Kurebayashi J; Moriya T; Ishida T; Hirakawa H; Kurosumi M; Akiyama F; Kinoshita T; Takei H; Takahashi K; Ikeda M; Nakashima K
Breast; 2007 Dec; 16 Suppl 2():S72-7. PubMed ID: 17714947
[TBL] [Abstract] [Full Text] [Related]
10. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.
Kurebayashi J; Okubo S; Yamamoto Y; Ikeda M; Tanaka K; Otsuki T; Sonoo H
Cancer Chemother Pharmacol; 2006 Oct; 58(4):460-70. PubMed ID: 16435154
[TBL] [Abstract] [Full Text] [Related]
11. Resistance to endocrine therapy in breast cancer.
Kurebayashi J
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of her1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.
Kurebayashi J; Okubo S; Yamamoto Y; Sonoo H
Breast Cancer; 2004; 11(1):38-41. PubMed ID: 14718791
[TBL] [Abstract] [Full Text] [Related]
13. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
Okubo S; Kurebayashi J; Otsuki T; Yamamoto Y; Tanaka K; Sonoo H
Br J Cancer; 2004 Jan; 90(1):236-44. PubMed ID: 14710235
[TBL] [Abstract] [Full Text] [Related]
14. Biological and clinical significance of HER2 overexpression in breast cancer.
Kurebayashi J
Breast Cancer; 2001; 8(1):45-51. PubMed ID: 11180765
[TBL] [Abstract] [Full Text] [Related]
15. [Amplification of the erbb-2 (Her-2/NEU), erbb-1 (HER-1) and c-myc oncogenes is often combined with the deletion of the short arm of chromosome 17 in human carcinoma].
Imianitov EN; Chernitsa OI; Nikiforova IF; Serova OM; Sokolov SI; Laur OIu; Togo AV; Kniazev PG
Mol Biol (Mosk); 1993; 27(4):888-94. PubMed ID: 8103188
[TBL] [Abstract] [Full Text] [Related]
